Archive \ Volume.17 2026 Issue 2

Conversational Pharmacovigilance That Preserves the Patient’s Narrative

, , ,
  1. Department of Conversational AI and Pharmacovigilance, Faculty of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
  2. Department of Patient Narrative in Drug Safety, Faculty of Pharmacy, University of Southampton, Southampton, United Kingdom.
  3. Department of AI and Patient Voice in Pharmacy, Faculty of Pharmacy, Newcastle University, Newcastle, United Kingdom.

Abstract

Structured adverse-event reporting supports coding, aggregation, and regulatory review, but it can compress the patient’s account into fields that omit chronology, uncertainty, functional consequences, perceived causality, and the language through which harm is understood. This article proposes a non-empirical conversational pharmacovigilance architecture designed to preserve patient narrative while supporting structured extraction, triage, and signal work. The architecture uses a dual-representation contract: an append-preserving narrative ledger remains the source record, while a separate structured safety object contains derived medication, event, timing, seriousness, outcome, action, and uncertainty fields linked to supporting narrative spans. A bounded clarification controller may request missing safety-relevant information without silently rewriting previous statements. The preserved narrative and structured derivative are combined in a paired triage packet and passed through explicit human review gates before case assessment or signal work. Governance spans consent, privacy, accessibility, patient correction, provenance, auditability, subgroup evaluation, incident response, change control, and withdrawal authority. Evaluation must distinguish narrative completeness and fidelity from coding accuracy, triage safety, workflow consequence, patient experience, equity, and organizational readiness. The architecture does not determine causality, replace professional assessment, provide medication advice, validate safety signals, or establish regulatory compliance. Its original contribution is a provenance-preserving relationship between patient dialogue and pharmacovigilance operations that treats structured data as a useful derivative rather than a superior replacement for the patient’s account. Empirical validation is required across languages, populations, reporting channels, and medication-safety workflows.


Downloads: 30
Views: 85

How to cite:
Vancouver
Bennett O, Collins H, Foster J, Wright E. Conversational Pharmacovigilance That Preserves the Patient’s Narrative. Arch Pharm Pract. 2026;17(2):4-12. https://doi.org/10.51847/HSMLaWFbcN
APA
Bennett, O., Collins, H., Foster, J., & Wright, E. (2026). Conversational Pharmacovigilance That Preserves the Patient’s Narrative. Archives of Pharmacy Practice, 17(2), 4-12. https://doi.org/10.51847/HSMLaWFbcN

Download Citation
References
  1. Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: A retrospective comparative analysis. Drug Saf. 2017;40(7):607-14. doi:10.1007/s40264-017-0530-5
  2. O’Donovan B, Rodgers RM, Cox AR, Krska J. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK Yellow Card Scheme. Br J Clin Pharmacol. 2022;88(7):3434-46. doi:10.1111/bcp.15263
  3. Gordijn R, Wessels W, Kriek E, Nicolai MPJ, Elzevier HW, Visser L, et al. Patient reporting of sexual adverse events on an online platform for medication experiences. Br J Clin Pharmacol. 2022;88(12):5326-35. doi:10.1111/bcp.15454
  4. Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: A systematic review. Int J Clin Pharm. 2023;45(6):1349-58. doi:10.1007/s11096-023-01592-y
  5. Rolfes L, van Hunsel F, Caster O, Taavola H, Taxis K, van Puijenbroek E. Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. Br J Clin Pharmacol. 2018;84(7):1514-24. doi:10.1111/bcp.13576
  6. Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: Results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018;41(2):203-12. doi:10.1007/s40264-017-0594-2
  7. de Vries ST, Denig P, Andrić A, Dimov Di Giusti M, Ptaszynska-Neophytou A, Härmark L, et al. Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, The Netherlands, and the UK. Drug Saf. 2021;44(10):1073-83. doi:10.1007/s40264-021-01098-4
  8. Robinson F, Wilkes S, Schaefer N, Goldstein M, Rice M, Gray J, et al. Patient-centered pharmacovigilance: Priority actions from the inherited bleeding disorders community. Ther Adv Drug Saf. 2023;14:20420986221146418. doi:10.1177/20420986221146418
  9. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf. 2021;44(2):125-32. doi:10.1007/s40264-020-01001-7
  10. Edrees H, Song W, Syrowatka A, Simona A, Amato MG, Bates DW. Intelligent telehealth in pharmacovigilance: A future perspective. Drug Saf. 2022;45(5):449-58. doi:10.1007/s40264-022-01172-5
  11. Leskur D, Bozic J, Rusic D, Seselja Perisin A, Cohadzic T, Pranic S, et al. Adverse drug reaction reporting via mobile applications: A narrative review. Int J Med Inform. 2022;168:104895. doi:10.1016/j.ijmedinf.2022.104895
  12. Kassekert R, Grabowski N, Lorenz D, Schaffer C, Kempf D, Roy P, et al. Industry perspective on artificial intelligence/machine learning in pharmacovigilance. Drug Saf. 2022;45(5):439-48. doi:10.1007/s40264-022-01164-5
  13. Laranjo L, Dunn AG, Tong HL, Kocaballi AB, Chen J, Bashir R, et al. Conversational agents in healthcare: A systematic review. J Am Med Inform Assoc. 2018;25(9):1248-58. doi:10.1093/jamia/ocy072
  14. Kocaballi AB, Berkovsky S, Quiroz JC, Laranjo L, Tong HL, Rezazadegan D, et al. The personalization of conversational agents in health care: Systematic review. J Med Internet Res. 2019;21(11). doi:10.2196/15360
  15. Tudor Car L, Dhinagaran DA, Kyaw BM, Kowatsch T, Joty S, Theng YL, et al. Conversational agents in health care: Scoping review and conceptual analysis. J Med Internet Res. 2020;22(8). doi:10.2196/17158
  16. Martin GL, Jouganous J, Savidan R, Bellec A, Goehrs C, Benkebil M, et al. Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data. Drug Saf. 2022;45(5):535-48. doi:10.1007/s40264-022-01153-8
  17. Létinier L, Jouganous J, Benkebil M, Bel-Létoile A, Goehrs C, Singier A, et al. Artificial intelligence for unstructured healthcare data: Application to coding of patient reporting of adverse drug reactions. Clin Pharmacol Ther. 2021;110(2):392-400. doi:10.1002/cpt.2266
  18. Wasylewicz A, van de Burgt B, Weterings A, Jessurun N, Korsten E, Egberts T, et al. Identifying adverse drug reactions from free-text electronic hospital health record notes. Br J Clin Pharmacol. 2022;88(3):1235-45. doi:10.1111/bcp.15068
  19. Davis SE, Zabotka L, Desai RJ, Wang SV, Maro JC, Coughlin K, et al. Use of electronic health record data for drug safety signal identification: A scoping review. Drug Saf. 2023;46(8):725-42. doi:10.1007/s40264-023-01325-0
  20. Golder S, Xu D, O’Connor K, Wang Y, Batra M, Hernandez GG. Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health/medical records: A scoping review. Drug Saf. 2025;48(4):321-37. doi:10.1007/s40264-024-01505-6
  21. Ding H, Simmich J, Vaezipour A, Andrews N, Russell T. Evaluation framework for conversational agents with artificial intelligence in health interventions: A systematic scoping review. J Am Med Inform Assoc. 2024;31(3):746-61. doi:10.1093/jamia/ocad222
  22. Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med. 2022;28(5):924-33. doi:10.1038/s41591-022-01772-9
  23. Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK, Chan AW, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension. Nat Med. 2020;26(9):1364-74. doi:10.1038/s41591-020-1034-x
  24. Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385. doi:10.1136/bmj-2023-078378
  25. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: A roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-40. doi:10.1038/s41591-019-0548-6
  26. Morley J, Machado CCV, Burr C, Cowls J, Joshi I, Taddeo M, et al. The ethics of AI in health care: A mapping review. Soc Sci Med. 2020;260:113172. doi:10.1016/j.socscimed.2020.113172
  27. Richardson JP, Smith C, Curtis S, Watson S, Zhu X, Barry B, et al. Patient apprehensions about the use of artificial intelligence in healthcare. NPJ Digit Med. 2021;4(1):140. doi:10.1038/s41746-021-00509-1
  28. Seyyed-Kalantari L, Zhang H, McDermott MBA, Chen IY, Ghassemi M. Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations. Nat Med. 2021;27(12):2176-82. doi:10.1038/s41591-021-01595-0
  29. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. doi:10.1186/s12916-019-1426-2
  30. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11). doi:10.1016/S2589-7500(21)00208-9
  31. Finlayson SG, Bowers JD, Ito J, Zittrain JL, Beam AL, Kohane IS. Adversarial attacks on medical machine learning. Science. 2019;363(6433):1287-9. doi:10.1126/science.aaw4399
  32. Subbaswamy A, Saria S. From development to deployment: Dataset shift, causality, and shift-stable models in health AI. Biostatistics. 2020;21(2):345-52. doi:10.1093/biostatistics/kxz041

 

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.